Screener / SEC EDGAR /CIK 0001178670 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Alnylam Pharmaceuticals, Inc. ALNY

Compare with peers Embed
FY2025 at a glance

Sales up 65.2%, free cash flow up to $465.4M

XBRL, from each 10-K
RevenueStatements
$3.7B from $2.2B in FY2024
FY2016FY2025
Net incomeStatements
$313.7M from -$278.2M in FY2024
FY2016FY2025
Free cash flowStatements
$465.4M from -$42.6M in FY2024
FY2016FY2025
EPS (diluted)Statements
$2.33 from $-2.18 in FY2024
FY2016FY2025
Operating marginStatements
13.5% from -7.9% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (40)
EPS (ttm)
19.24
Sales (ttm)
5.0B
Net income (ttm)
2.6B
Sales growth
+65.2%
EPS growth
-
Sales Q/Q
+16.7%
Free cash flow
806.3M
Gross margin
77.4%
Oper. margin
19.5%
Net margin
52.8%
FCF margin
16.1%
R&D / sales
35.5%
Dividend
-
Debt/Eq
-
Curr. ratio
2.48
Cash
1.8B
Op. cash flow (ttm)
955.9M
EBITDA
557.2M
EBITDA margin
15.0%
Quick ratio
2.44
Interest cover
1.99
ROIC
13.5%
FCF after stock pay
117.1M
Oper. margin low 5y
-83.9%
Tax rate
2.9%
Stock pay / sales
9.4%
Shares out.
133.9M
Shares Y/Y
+5.5%
Book / share
26.91
Cash / share
13.10
Sales / share
37.43
Asset turnover
0.63
Inventory turns
8.19
Days sales out.
76
Sales 3Y CAGR
+53.0%
Sales 5Y CAGR
+49.8%
Employees
2,500
Sales / employee
2.0M

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 3.7B +62.4% a year Net income 313.7M
FY2016 revenue 47.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-19-003022 FY2016 net income -410.1M · NetIncomeLoss, 0001564590-19-003022 47.2M FY2016 FY2017 revenue 89.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001178670-20-000004 FY2017 net income -490.9M · NetIncomeLoss, 0001178670-20-000004 89.9M FY2017 FY2018 revenue 74.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001178670-21-000010 FY2018 net income -761.5M · NetIncomeLoss, 0001178670-21-000010 74.9M FY2018 FY2019 revenue 219.8M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001178670-21-000010 FY2019 net income -886.1M · NetIncomeLoss, 0001178670-22-000013 219.8M FY2019 FY2020 revenue 492.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001178670-21-000010 FY2020 net income -858.3M · NetIncomeLoss, 0001178670-23-000005 492.9M FY2020 FY2021 revenue 844.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001178670-24-000008 FY2021 net income -852.8M · NetIncomeLoss, 0001178670-24-000008 844.3M FY2021 FY2022 revenue 1.0B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001178670-25-000026 FY2022 net income -1.1B · NetIncomeLoss, 0001178670-25-000026 1.0B FY2022 FY2023 revenue 1.8B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-007497 FY2023 net income -440.2M · NetIncomeLoss, 0001628280-26-007497 1.8B FY2023 FY2024 revenue 2.2B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-007497 FY2024 net income -278.2M · NetIncomeLoss, 0001628280-26-007497 2.2B FY2024 FY2025 revenue 3.7B · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-007497 FY2025 net income 313.7M · NetIncomeLoss, 0001628280-26-007497 3.7B FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share -12.6% a year FY2019 $13.17 to FY2025 $5.86, 6 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $2.33$5.86$3.46
Dec 31, 2024 -$2.18$0.53-$0.33
Dec 31, 2023 -$3.52-$1.77$0.34
Dec 31, 2022 -$9.30-$1.30-$5.04
Dec 31, 2021 -$7.20$4.97-$6.06
Dec 31, 2020 -$7.46$8.84-$5.96
Dec 31, 2019 -$8.11$13.17-$3.83
Dec 31, 2018 ---
Dec 31, 2017 ---
Dec 31, 2016 ---
Dec 31, 2015 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $4.1B
  • − All liabilities $4.2B
  • = Net current asset value -$126.5M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $789.2M
  • = Tangible book value $789.2M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

ALNY against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+65.2%12th of 155 · median +10.5%
Net margin
-4.1%15.3%
52.8%2nd of 154 · median 6.8%
Return on equity
-5.2%18.5%
73.5%4th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
16.1%46th of 145 · median 10.0%
ALNY and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
ALNY Alnylam Pharmaceuticals, Inc.$5.0B +65.2%77.4%52.8%73.5%16.1%-
ELAN Elanco Animal Health Inc$5.1B +6.2%56.2%-2.9%-2.2%7.9%0.52
DXCM Dexcom$5.1B +15.6%63.4%19.4%39.1%21.5%-
JAZZ Jazz Pharmaceuticals plc$4.7B +4.9%-4.4%4.9%34.4%1.33
IDXX Idexx Laboratories$4.7B +10.4%62.7%25.4%63.2%28.0%0.20
ILMN Illumina, Inc.$4.5B -0.7%67.9%19.7%28.5%23.3%0.57
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement and revenue by product

From $3.7B of sales to $313.7M of profit FY2025

  • AMVUTTRA $2.3B
  • Collaborations $553.4M
  • GIVLAARI $308.5M
  • OXLUMO $191.4M
  • Royalty revenue $174.0M
  • ONPATTRO $172.8M
Revenue to Gross profit: $3.0BRevenue to Cost of revenue: $677.2MGross profit to Operating profit: $501.6MGross profit to Operating expenses: $2.5BOperating profit to Net profit: $313.7MOperating profit to Tax & other: $187.8MOperating expenses to R&D: $1.3BOperating expenses to SG&A: $1.2B Revenue: $3.7B REVENUE $3.7B +65% Y/Y Gross profit: $3.0B · 82% margin GROSS PROFIT $3.0B 82% margin Cost of revenue: $677.2M · 18% of revenue COST OF REVENUE $677.2M 18% of revenue Operating profit: $501.6M · 14% margin OPERATING PROFIT $501.6M 14% margin Operating expenses: $2.5B · 68% of revenue OPERATING EXPENSES $2.5B 68% of revenue Net profit: $313.7M · 8% margin NET PROFIT $313.7M 8% margin Tax & other: $187.8M · 5% of revenue TAX & OTHER $187.8M 5% of revenue R&D: $1.3B · 36% of revenue R&D $1.3B 36% of revenue SG&A: $1.2B · 33% of revenue SG&A $1.2B 33% of revenue

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 39.8% FY2020: -84.5% net income ÷ equity
Net margin 8.4% FY2020: -174.1% profit per $ of sales: 313.7M ÷ 3.7B
Asset turnover 0.75× FY2020: 0.14× sales per $ of assets: 3.7B ÷ 5.0B
Leverage 6.29× FY2020: 3.35× assets per $ of equity: 5.0B ÷ 789.2M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    52.8% vs 6.8%
  • Return on equity above 15%
    73.5%
  • A profit in 1 of 10 years
Net margin, FY2016 to FY2025: -869.6% to 8.4%

Balance sheet

  • Interest covered less than 5 times
    Operating income is 2.0× interest expense
  • Current assets cover current liabilities
    Current ratio 2.48
Debt / equity at each year end, FY2016 to FY2025: 0.19 to 1.15

Cash and shareholders

  • Free cash flow positive in 2 of 10 years
    $465.4M last year
  • Share count up over 5 years
    +17.1%
  • Cash from operations above net income
    $524.1M vs $313.7M
Free cash flow, FY2016 to FY2025: -372.3M to 465.4M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Contracted revenue and deferred revenue

Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL

Contract liabilities, current part

Paid in advance $11.7M cash received before delivery, not yet recognized as revenue, Sep 30, 2026 · +359.2% on a year earlier

Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

ALNY's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue3.7B
FY2016: 47.2MFY2017: 89.9MFY2018: 74.9MFY2019: 219.8MFY2020: 492.9MFY2021: 844.3MFY2022: 1.0BFY2023: 1.8BFY2024: 2.2BFY2025: 3.7B FY2017FY2019FY2021FY2023FY2025
Net income313.7M
FY2016: -410.1MFY2017: -490.9MFY2018: -761.5MFY2019: -886.1MFY2020: -858.3MFY2021: -852.8MFY2022: -1.1BFY2023: -440.2MFY2024: -278.2MFY2025: 313.7M FY2017FY2019FY2021FY2023FY2025
Free cash flow465.4M
FY2016: -372.3MFY2017: -487.0MFY2018: -689.5MFY2019: -418.6MFY2020: -685.3MFY2021: -718.1MFY2022: -613.3MFY2023: 41.9MFY2024: -42.6MFY2025: 465.4M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay117.1M
FY2016: -447.8MFY2017: -579.8MFY2018: -847.3MFY2019: -593.4MFY2020: -825.2MFY2021: -883.8MFY2022: -844.0MFY2023: -179.7MFY2024: -314.7MFY2025: 117.1M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)2.33
FY2016: -4.79FY2017: -5.42FY2018: -7.57FY2019: -8.11FY2020: -7.46FY2021: -7.20FY2022: -9.30FY2023: -3.52FY2024: -2.18FY2025: 2.33 FY2017FY2019FY2021FY2023FY2025
Diluted shares134.7M
FY2016: -FY2017: -FY2018: -FY2019: 109.3MFY2020: 115.0MFY2021: 118.5MFY2022: 121.7MFY2023: 124.9MFY2024: 127.7MFY2025: 134.7M FY2017FY2019FY2021FY2023FY2025

Revenue by product or service

year to Dec 31, 2025
RevenueSharevs year before
TTR 2.5B67.0% +103%
AMVUTTRA 2.3B62.3% +138%
Collaborations 553.4M14.9% +8.5%
Rare 499.9M13.5% +18.2%
GIVLAARI 308.5M8.3% +20.6%
OXLUMO 191.4M5.2% +14.6%
Royalty revenue 174.0M4.7% +89.6%
ONPATTRO 172.8M4.7% -31.7%

10-K 0001628280-26-007497, segment and revenue notes (XBRL).

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue47.2M89.9M74.9M219.8M492.9M844.3M1.0B1.8B2.2B3.7B
Cost of revenue-01.8M25.1M74.2M115.0M140.2M268.2M306.5M677.2M
R&D382.4M390.6M505.4M655.1M654.8M792.2M883.0M1.0B1.1B1.3B
SG&A89.4M199.4M382.4M479.0M588.4M620.6M770.7M795.6M975.5M1.2B
Operating income-424.6M-500.1M-814.7M-939.4M-828.4M-708.7M-785.1M-282.2M-176.9M501.6M
Interest expense1.1M2.4M0084.5M143.0M156.0M121.2M141.9M252.6M
Pretax income-410.1M-490.9M-760.7M-885.3M-855.6M-852.1M-1.1B-433.5M-377.4M323.2M
Income tax00823K863K2.7M680K4.2M6.7M-99.2M9.4M
Net income-410.1M-490.9M-761.5M-886.1M-858.3M-852.8M-1.1B-440.2M-278.2M313.7M
EPS (diluted)-4.79-5.42-7.57-8.11-7.46-7.20-9.30-3.52-2.182.33
Diluted shares---109.3M115.0M118.5M121.7M124.9M127.7M134.7M
Depreciation & amortization15.1M13.4M15.2M17.2M34.8M47.6M44.5M54.1M56.7M55.7M
EBITDA-409.5M-486.7M-799.4M-922.3M-793.7M-661.1M-740.6M-228.1M-120.2M557.2M
Operating margin-900.3%-556.2%-1087.6%-427.5%-168.1%-83.9%-75.7%-15.4%-7.9%13.5%
Net margin-869.6%-545.9%-1016.6%-403.2%-174.1%-101.0%-109.0%-24.1%-12.4%8.4%
Revenue growth-+90.7%-16.7%+193%+124%+71.3%+22.9%+76.2%+23.0%+65.2%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-307.7M-382.8M-562.6M-278.4M-615.0M-641.7M-541.3M104.2M-8.3M524.1M
Capital spending64.6M104.2M126.9M140.2M70.4M76.4M72.1M62.2M34.3M58.7M
Free cash flow-372.3M-487.0M-689.5M-418.6M-685.3M-718.1M-613.3M41.9M-42.6M465.4M
Stock-based pay (added back)75.5M92.8M157.8M174.8M139.9M165.7M230.6M221.7M272.1M348.2M
Free cash flow after stock pay-447.8M-579.8M-847.3M-593.4M-825.2M-883.8M-844.0M-179.7M-314.7M117.1M
Debt repaid----00762.1M---
Investing cash flow142.6M-290.4M272.9M-417.7M-435.5M-273.3M169.4M-336.4M-116.8M436.3M
Financing cash flow177.8M1.1B65.5M823.2M995.0M1.2B425.8M172.1M294.2M-305.2M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)75.5M92.8M157.8M174.8M139.9M165.7M230.6M221.7M272.1M348.2M
Stock-based pay / revenue160.2%103.2%210.6%79.6%28.4%19.6%22.2%12.1%12.1%9.4%
Operating lease cost---38.6M42.3M45.4M45.8M46.4M46.0M49.8M
Operating lease cash paid---33.7M38.0M41.9M43.1M46.5M51.0M50.7M
Right-of-use assets--230.0M221.2M241.5M231.7M215.1M199.7M191.1M194.9M
Operating lease liabilities--290.0M303.8M329.9M321.9M303.3M284.6M271.4M270.6M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ALNY/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.